Gordon Naylor, who stepped into the interim chief executive role in February, has completed a 90-day review and set out a plan to accelerate the company’s transformation. …
CSL signals course correction as interim CEO outlines revised outlook and major impairments
May 11, 2026 Latest NewsBioPharmaAustralian BiotechNews of the Day
Latest Video
New Stories
-
Funding for new chemotherapy-free immunotherapy combination for follicular lymphoma
August 3, 2026 - - Latest News -
The HTA Review and the 'Abilene paradox' - when everyone argues for reforms that nobody wants
August 3, 2026 - - Latest News -
First new brain cancer treatment listed on PBS after more than 20 years
August 3, 2026 - - Latest News -
Listing offers treatment option for Australians with tumour induced osteomalacia
August 3, 2026 - - Latest News -
The 'Dispatched' Week in Review' Podcast - 31 July
July 31, 2026 - - Podcast -
New partnership aims to create national blueprint for earlier Alzheimer’s diagnosis and care
July 31, 2026 - - Latest News -
Industry associations still resisting non-disclosure agreements for negotiation
July 31, 2026 - - Latest News